超越第一次感染:探索儿科阿辛托巴克特病例的复发情况
Metehan Yaşar Tekin1, Saliha Kanik-Yüksek2, Belgin Gülhan3
1From the Department of Pediatrics.
The Pediatric infectious disease journal
|March 4, 2026
概括
在儿童中,反复出现的Acinetobacter感染 (AIs) 会导致住院时间更长,死亡率更高. 识别患有潜在疾病的危险儿科患者对于更好的管理和改善结果至关重要.
科学领域:
- 儿童传染病 儿童传染病
- 临床微生物学 临床微生物学
- 医院流行病学 医院流行病学
背景情况:
- 复发性Acinetobacter感染 (AIs) 带来了重大的治疗挑战,并增加了医疗保健成本.
- 关于儿科复发性AI的数据有限,需要进行表征以进行有效的管理.
研究的目的:
- 确定儿科患者复发性Acinetobacter感染的临床和微生物特征.
- 确定与反复出现的AI相关的风险因素及其对结果的影响.
主要方法:
- 2019年至2024年期间住院治疗确诊AI的儿科患者 (0-18岁) 的回顾性评估.
- 复发性AI的定义:在恢复后90天内出现新发作,并且有负面培养.
- 对临床,微生物学,实验室数据,治疗方法和结果的分析.
主要成果:
- 在150名儿科AI患者中,有15.3%患有复发性感染,与管和血液感染有关.
- 复发性AI与更长的住院时间和增加的死亡率 (总体为47.8%与34.7%) 有关.
- 多种药物或广泛抗药性单体很常见 (66.7%);死亡风险因素包括ICU入院和特定实验室发现.
结论:
- 儿科复发性AI显著增加住院时间和死亡风险.
- 识别高风险儿科患者,特别是那些患有并发症和危急疾病的儿科患者,至关重要.
- 加强监测和有针对性的干预措施对于改善经常性儿科AI病例的结果至关重要.
相关概念视频
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
542
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
542
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
342
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
342
01:27Acute Pyelonephritis I: Introduction
902
Pyelonephritis is a bacterial infection that primarily affects the renal parenchyma and collecting system, including the renal pelvis, tubules, and interstitial tissue of one or both kidneys. It can be classified as either acute—a sudden, severe infection—or chronic, which refers to long-term or recurrent kidney infections.The primary cause of acute pyelonephritis (APN) is bacterial infection, with Escherichia coli accounting for approximately 70-80% of cases. Other bacteria, such...
902
01:28Pneumonia IV: Management
975
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
975
01:30Pneumonia I: Introduction
1.1K
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.1K
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
303
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
303